News
MACK
14.77
+0.14%
0.02
Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
TipRanks · 1d ago
Merrimack receives $225M milestone payment from Ipsen
Merrimack Pharmaceuticals, Inc. Receives $225M milestone payment from Ipsen. Healthcare Merrimack receives approval to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas. The company has announced a special meeting of stockholders on May 10, 2024.
Seeking Alpha · 1d ago
Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable
The company has received a $225 million payment which was due from Ipsen, S.A. To market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas. Merrimack announced a special meeting of stockholders on May 10, 2024 to approve a liquidating dividend.
Benzinga · 1d ago
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Pharmaceuticals, Inc. Announced it has received a $225 million payment from Ipsen, S.A. The payment was due as a result of approval of ONIVYDE to market on the pancreas. Merrimack has announced a special meeting of stockholders on May 10, 2024 to approve a Plan of Dissolution. The company is entitled to $450.0 million in contingent milestone payments.
Barchart · 1d ago
Weekly Report: what happened at MACK last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at MACK last week (0311-0315)?
Weekly Report · 03/18 10:01
Weekly Report: what happened at MACK last week (0304-0308)?
Weekly Report · 03/11 10:00
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023
Merrimack Pharmaceuticals reported earnings per share of -1 per cent. The company did not report any revenue for the quarter. Merrimack is not listed as a stock to buy on the S&P 500 on Monday. The stock was down 1 per cent at the close of trading.
Investorplace · 03/08 13:51
Merrimack Pharmaceuticals reports FY results
Merrimack Pharmaceuticals reports FY GAAP EPS of -$0.08. As of December 31, 2023, Merrimack had cash, cash equivalents and short-term investments of $18.9 million. The company expects to report FY results on March 7.
Seeking Alpha · 03/07 22:27
Merrimack Pharmaceuticals Proposes Liquidation Plan
TipRanks · 03/07 21:52
*Merrimack Pharmaceuticals 2023 Loss/Shr 8c >MACK
Dow Jones · 03/07 21:32
*Merrimack Pharmaceuticals 2023 Loss $1.2M >MACK
Dow Jones · 03/07 21:32
BRIEF-Merrimack Pharmaceuticals FY EPS USD -0.08
Reuters · 03/07 21:30
Press Release: Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. Reports full year 2023 financial results for the period ended December 31, 2023. Merrimack reported net loss of $1.2 million for the year ended 2023 and expects to receive a $225 million payment from Ipsen S.A. In March 2024. The company is entitled to receive up to $450 million in contingent milestone payments for Onivyde.
Dow Jones · 03/07 21:30
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. Announced its full year 2023 financial results for the period ended December 31, 2023. Merrimack reported a net loss of $1.2 million for the year ended 2023 and a gain on sale of assets of $0.1 million. The company is entitled to receive a $225 million milestone payment for Onivyde.
Barchart · 03/07 15:30
Weekly Report: what happened at MACK last week (0226-0301)?
Weekly Report · 03/04 10:01
Weekly Report: what happened at MACK last week (0219-0223)?
Weekly Report · 02/26 10:07
Weekly Report: what happened at MACK last week (0212-0216)?
Weekly Report · 02/19 10:08
Merrimack Pharmaceuticals to Hold Meeting on Corporate Dissolution
Merrimack Pharmaceuticals plans to hold a special shareholder meeting to approve a plan for a corporate dissolution. The biopharmaceutical company will receive proceeds from a $225 million milestone payment from Ipsen. This comes after the FDA approved a new drug application for Merrimack's pancreatic cancer treatment.
Dow Jones · 02/13 22:23
Ipsen's Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA
Onivyde regimen (NALIRIFOX) approved for first-line treatment in adults living with metastatic pancreatic adenocarcinoma. Approval based on Phase III NAPOLI 3 clinical trial in which Onivy de demonstrated superior overall survival versus the currently approved regimen of nab-paclitaxel and gemcitabine. First positive Phase III trial in first-liners of pancreatic cancer and only FDA-approved treatment regimen to demonstrate efficacy.
Benzinga · 02/13 21:50
More
Webull provides a variety of real-time MACK stock news. You can receive the latest news about Merrimack Pharma through multiple platforms. This information may help you make smarter investment decisions.
About MACK
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.